All CME lectures available on the Academy are included in this package (over 400 hours of education).

For one year, get access to 100% of the clinical content available* on the Obesity Medicine Academy at an unbeatable discounted rate! Earn CME/CE credit and gain crucial knowledge and clinically applicable treatment strategies, all while learning from industry thought leaders, published journal authors, and your colleagues in the field of obesity medicine. 

*All Access Pass excludes Lifestyle Therapeutics Certificate programs, student and resident rotations, and Self Assessment Programs

This Lecture is free! Just put it in your cart and check out - you will not have to pay anything.  

Contact Hours Expiration Date: *10/31/2018
*The expiration date listed above is the last day contact hours can be claimed for this specific presentation.

This activity is supported by an independent educational grant from Novo Nordisk, Inc.

Description: 

This panel discussion of obesity medicine experts discusses the use of the various available obesity guidelines and algorithms in evaluating patients for treatment.

Disclosures (at time of recording): Speaker(s):

• Deborah Bade Horn, DO, MPH, MFOMA
  • Novo Nordisk, Inc.: Speakers Bureau, Honoraria, and Advisory Activities
  • Orexigen Therapeutics, Inc.: Speakers Bureau, Honoraria, and Advisory Activities
• Scott Kahan, MD, MPH, FTOS
  • Novo Nordisk, Inc.: Speakers Bureau, Honoraria, and Development of Educational Activities
  • Takeda Pharmaceuticals U.S.A., Inc.: Speakers Bureau, Honoraria, and Development of Educational Activities
  • Orexigen Therapeutics, Inc.: Development of Educational Activities 
• Chris Still, DO, FACN, FACP
  • Novo Nordisk, Inc.: Speakers Bureau, Honoraria, Advisory Activities, and Research Activities
  • Takeda Pharmaceuticals U.S.A., Inc.: Speakers Bureau, Honoraria, and Advisory Activities
  • Ethicon, Inc. (endosurgery): Advisory Activities and Research Activities

Planners:

• Nothing to Disclose: Robert Dougherty; Dana Mansell, CHCP; William McCarthy, MD, FOMA; Lauren Rieck; James Schiffer, RPh; Laurie Traetow, CAE

Accreditation:  

Maxtrix Medical Communications (California Board of Registered Nursing Approved Provider # 14887) designates this enduring material internet activity for a maximum of 1.5 contact hours.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Obesity Medicine Association and CE Health Interactive. The Obesity Medicine Association is accredited by the ACCME to provide continuing medical education for physicians.

This program was produced by Matrix Medical Communications and was originally recorded on September 9, 2016.

*Note: All information and materials provided has expired for CME credit possibilities and is solely to be used for informational purposes only.

Description: 

Sugar's potential for abuse, coupled with its toxicity and pervasiveness in the western diet, make it a primary culprit of the obesity epidemic. Sugar changes metabolism, raises blood pressure, critically alters the signaling of hormones and causes significant damage to the liver. This presentation will make the case for sugar to be controlled like alcohol and tobacco to protect public health.

Disclosures (at time of recording):  Speaker:

• Robert Lustig, MD, MSL: Nothing to disclose

Planners:

• William McCarthy, MD, FOMA: Ridgetop Research: Offered Expert Opinion on Qsymia
• Craig Primack, MD, FACP, FOMA: Nestle: Speaker, Focus Group Member; VIVUS: Speaker, Consultant; Diet Owl Smart Phone Application: Founder
• Eric Westman, MD, MHS, MFOMA: VIVUS, Inc.: National Advisory Board and Speaker’s Bureau; KE Diet: Scientific Advisory Board Member
• Nothing to Disclose: Sandra Christensen, MSN, ARNP, FOMA; Krishna Doniparthi, MD, FOMA; U. Inge Ferguson, DO, FACOI, FOMA; Brent Gear, DO; Charles Halliman; Deborah Bade Horn, DO, MPH, MS, MFOMA; Carl Knopke, MD, FOMA; Dana Mansell; Jeremy McConnell, MD, FOMA; Timothy McCormick, DO, MPH; Daisy Merey, MD, PhD; Scott Rigden, MD, FAAFP, MFOMA; Stacy Schmidt, PhD; Jennifer Seger, MD, FOMA; Harold Seim, MD, MPH, FOMA; Laurie Traetow, CAE

*Note: All information and materials provided has expired for CME credit possibilities and is solely to be used for informational purposes only.

Description: 

This question and answer panel delves deeper into three diet types: the Mediterranean diet, a carbohydrate-restricted diet, and a vegetarian/vegan diet.

Disclosures (at time of recording): Speakers:

• Michael Ozner, MD, FACC, FAHA: Life Extension Foundation: Advisory Activities; Nordic Naturals: Advisory Activities 
• Krishna Doniparthi, MD, FOMA: Nothing to disclose
• William S. Yancy Jr., MD, MHS: Nothing to disclose 

Planners:

• Nothing to Disclose: Marcie Gonzales; Carl Knopke, MD, FOMA; Dana Mansell, CHCP; William McCarthy, MD, FOMA; Stacy Schmidt, PhD; Laurie Traetow, CAE

*Note: All information and materials provided has expired for CME credit possibilities and is solely to be used for informational purposes only.

Description:

The panel will deliberate about the benefits of using a low-carbohydrate or low-fat approach for diabetes treatment.

Disclosures (at time of recording):   Speakers:

• John Foreyt, PhD: Nothing to disclose
• Kevin C. Maki, PhD, CLS, FNLA, FTOS: Kellogg: Advisory Board and Research; National Dairy Council: Advisory Board and Research; American Egg Board: Advisory Board and Research; National Cattleman’s Beef Association: Advisory Board and Research; Biofortis: Advisory Board
• William S. Yancy, Jr., MD, MHS: NutriSystem: Advisory Board; Weight Watchers: Research; ViiV Healthcare: Spouse Part-time Employment

Planners:

• Eric C. Westman, MD, MHS: Vivus: Speakers Bureau; Eisai: Speakers Bureau; KE Diet: Advisory Board; Invoy: Advisory Board; Low Carbohydrate Ketogenic Diet Manual: Royalties; Cholesterol Clarity: Royalties; Keto Clarity: Royalties; Low Carb Adapt Website: Co-founder
• Nothing to Disclose: Richard David Feinman, PhD; Dana Mansell, CHCP; William McCarthy, MD; Stacy Schmidt, PhD; Laurie Traetow, CAE

*Note: All information and materials provided has expired for CME credit possibilities and is solely to be used for informational purposes only.

Description: The incretin hormone GLP-1 acts as a satiety hormone, making it a potentially attractive target for the treatment of obesity. This lecture will discuss mechanisms by which GLP-1 affects satiety, review the efficacy of GLP-1-based therapies as weight loss agents in patients with type 2 diabetes, and include preliminary clinical trial data in patients without diabetes mellitus. The safety and current concerns surrounding this type of therapy will also be reviewed.

Disclosures (at time of recording):  Speaker:

• Barbara McGowan, MD, FRCP, PhD: Novo Nordisk: Principal Investigator – SCALE Study and Administrative Board Member

Planners:

• William McCarthy, MD, FOMA: Ridgetop Research: Offered Expert Opinion on Qsymia
• Craig Primack, MD, FACP, FOMA: Nestle: Speaker, Focus Group Member; VIVUS: Speaker, Consultant; Diet Owl Smart Phone Application: Founder
• Eric Westman, MD, MHS, MFOMA: VIVUS, Inc.: National Advisory Board and Speaker’s Bureau; KE Diet: Scientific Advisory Board Member
• Nothing to Disclose: Sandra Christensen, MSN, ARNP, FOMA; Krishna Doniparthi, MD, FOMA; U. Inge Ferguson, DO, FACOI, FOMA; Brent Gear, DO; Charles Halliman; Deborah Bade Horn, DO, MPH, MS, MFOMA; Carl Knopke, MD, FOMA; Dana Mansell; Jeremy McConnell, MD, FOMA; Timothy McCormick, DO, MPH; Daisy Merey, MD, PhD; Scott Rigden, MD, FAAFP, MFOMA; Stacy Schmidt, PhD; Jennifer Seger, MD, FOMA; Harold Seim, MD, MPH, FOMA; Laurie Traetow, CAE